From the Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center.
Plast Reconstr Surg. 2022 Apr 1;149(4):607e-616e. doi: 10.1097/PRS.0000000000008892.
Prepectoral placement of tissue expanders for two-stage implant-based breast reconstruction potentially minimizes chest wall morbidity and postoperative pain. The authors explored 90-day clinical and health-related quality-of-life outcomes for prepectoral versus subpectoral tissue expander breast reconstruction.
The authors conducted a propensity score-matching analysis (nearest neighbor, 1:1 matching without replacement) of patients who underwent immediate prepectoral or subpectoral tissue expander breast reconstruction between December of 2017 and January of 2019. Matched covariates included age, body mass index, race/ethnicity, smoking status, chemotherapy, radiotherapy, nipple-sparing mastectomy, and laterality of reconstruction. Outcomes of interest were perioperative analgesia use, 90-day postoperative patient-reported pain, complication rates, and BREAST-Q physical well-being of the chest scores.
Of the initial cohort of 921 patients, 238 were propensity-matched and included in the final analysis. The matched cohort had no differences in baseline characteristics. Postoperative ketorolac (p = 0.048) use was higher in the subpectoral group; there were no other significant differences in intraoperative and postoperative analgesia use. Prepectoral patients had lower pain on postoperative days 1 to 2 but no differences on days 3 to 10. BREAST-Q physical well-being of the chest scores did not differ. Prepectoral patients had higher rates of seroma than subpectoral patients (p < 0.001). Rates of tissue expander loss did not differ.
This matched analysis of 90-day complications found lower early postoperative pain in prepectoral tissue expander patients but no longer-term patient-reported differences. Although prepectoral reconstruction patients experienced a higher rate of seroma, this did not translate to a difference in tissue expander loss. Long-term analysis of clinical and patient-reported outcomes is needed to understand the full profile of the prepectoral technique.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
用于二期基于植入物的乳房重建的胸肌前置组织扩张器有可能将胸壁发病率和术后疼痛降到最低。作者研究了胸肌前置与胸肌下置组织扩张器乳房重建的 90 天临床和健康相关生活质量结果。
作者对 2017 年 12 月至 2019 年 1 月期间接受即刻胸肌前置或胸肌下置组织扩张器乳房重建的患者进行了倾向评分匹配分析(最近邻,1:1 无替换匹配)。匹配的协变量包括年龄、体重指数、种族/民族、吸烟状况、化疗、放疗、保留乳头的乳房切除术和重建的侧别。感兴趣的结果是围手术期镇痛使用、90 天术后患者报告的疼痛、并发症发生率和 BREAST-Q 胸部物理健康评分。
在最初的 921 例患者队列中,238 例进行了倾向评分匹配并纳入最终分析。匹配队列在基线特征上没有差异。胸肌下置组术后使用酮咯酸(p=0.048)较高;术中及术后镇痛使用无其他显著差异。胸肌前置患者术后第 1 至 2 天疼痛较低,但第 3 至 10 天无差异。BREAST-Q 胸部物理健康评分无差异。胸肌前置患者的血清肿发生率高于胸肌下置患者(p<0.001)。组织扩张器丢失率无差异。
这项 90 天并发症的匹配分析发现,胸肌前置组织扩张器患者的早期术后疼痛较低,但在患者报告的长期差异方面没有发现。尽管胸肌前置重建患者的血清肿发生率较高,但这并未转化为组织扩张器丢失的差异。需要对临床和患者报告的结果进行长期分析,以了解胸肌前置技术的全貌。
临床问题/证据水平:治疗性,III 级。